US 12,297,218 B2
Complex comprising a PSMA-targeting compound linked to a lead or thorium radionuclide
Roy Hartvig Larsen, Oslo (NO)
Assigned to SCIENCONS AS, Oslo (NO)
Filed by Sciencons AS, Oslo (NO)
Filed on Nov. 9, 2023, as Appl. No. 18/505,688.
Application 18/505,688 is a continuation of application No. 16/771,596, abandoned, previously published as PCT/EP2018/084738, filed on Dec. 13, 2018.
Claims priority of application No. 17206887 (EP), filed on Dec. 13, 2017.
Prior Publication US 2024/0182501 A1, Jun. 6, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07F 7/24 (2006.01); A61K 51/04 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); C07B 59/00 (2006.01); C07F 3/00 (2006.01); C07F 9/94 (2006.01)
CPC C07F 7/24 (2013.01) [A61K 51/0402 (2013.01); A61K 51/0497 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07B 59/002 (2013.01); C07F 3/003 (2013.01); C07F 9/94 (2013.01); C07B 2200/05 (2013.01)] 20 Claims
 
1. A complex comprising:
a) a compound having the formula of

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein,
Z is p-SCN-Bn-TCMC; and
b) a radionuclide complexed with the TCMC, wherein the radionuclide is 212Pb.